Evidence map›Paper›PMID 35837106›Full record

ArticleFrontiers in oncology2022

An Orthotopic Patient-Derived Xenograft (PDX) Model Allows the Analysis of Metastasis-Associated Features in Colorectal Cancer.

Maria Laura De Angelis, Federica Francescangeli, Chiara Nicolazzo, Eljona Xhelili, Filippo La Torre, Lidia Colace, Alessandro Bruselles, Daniele Macchia, Sara Vitale, Paola Gazzaniga and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Maria Laura De AngelisDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Federica FrancescangeliDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Chiara NicolazzoDepartment of Molecular Medicine, Liquid Biopsy Unit, Sapienza University, Rome, Italy.
Eljona XheliliSurgical Sciences and Emergency Department, Policlinico Umberto I/Sapienza University of Rome, Rome, Italy.
Filippo La TorreSurgical Sciences and Emergency Department, Policlinico Umberto I/Sapienza University of Rome, Rome, Italy.
Lidia ColaceDepartment of Surgical Sciences, Policlinico Umberto I/Sapienza University of Rome, Rome, Italy.
Alessandro BrusellesDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Daniele MacchiaCenter of Animal research and Welfare, Istituto Superiore di Sanità, Rome, Italy.
Sara VitaleDepartment of Medicine and Traslational Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
Paola GazzanigaDepartment of Molecular Medicine, Liquid Biopsy Unit, Sapienza University, Rome, Italy.
Marta BaiocchiDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Ann ZeunerDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Istituto Superiore di Sanità · ITSapienza University of Rome · ITPoliclinico Umberto I · ITUniversità Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastasis is the primary cause of death in patients with colorectal cancer (CRC), urging the need for preclinical models that recapitulate the metastatic process at the individual patient level. We used an orthotopic patient-derived xenograft (PDX) obtained through the direct implantation of freshly dissociated CRC cells in the colon of immunocompromised mice to model the metastatic process. Ortho-PDX engraftment was associated to a specific set of molecular features of the parental tumor, such as epithelial-to-mesenchymal transition (EMT), TGF-β pathway activation, increased expression of stemness-associated factors and higher numbers of circulating tumor cells (CTCs) clusters expressing the metastatic marker CD44v6. A parallel analysis of orthotopic/metastatic xenografts and organoids showed that tumor cells underwent mesenchymal-to-epithelial transition at the metastatic site and that metastasis-derived organoids had increased chemotherapy resistance. These observations support the usefulness of ortho-PDX as a preclinical model to study metastasis-related features and provide preliminary evidence that EMT/stemness properties of primary colorectal tumors may be crucial for orthotopic tumor engraftment.

Indexed as

colorectal cancer (CRC)epithelial-to-mesenchymal transition (EMT)metastasisorganoidspatient-derived xenograft (PDX)

Identifiers

PMID35837106
PMCPMC9275818
OpenAlexW4283653621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.